ОТНОСТНО ТОЗИ ЕПИЗОД
Andre Esteva is the CEO and Co-Founder of Artera, a company focused on improving prostate cancer diagnostics. The company uses an AI-driven test, validated in large-scale clinical trials, to analyze a tumor biopsy or surgical specimen and predict response to therapy and likely long-term outcomes. This helps inform treatment decisions, reduce the risk of over-treatment, and support healthcare equity in diverse patient populations. Plans are underway to expand the AI-driven diagnostic tools to other solid tumor types leveraging the ability of AI to learn across different cancers.
Andre explains, "In general, when it comes to the treatment of prostate cancer, and this is true for most cancers, clinicians tend to be conservative, rightfully so, and there is a tendency to overtreat patients. You see, when it comes to assigning a therapy to a patient, there's this notion of the optimal therapy, and you want to get it right. If you undertreat your patient, the disease will progress, and nobody wants their cancer to progress. So as a result, patients tend to be overtreated when too much therapy is applied. While that does support killing the cancer, it also comes with a series of negative side effects. Real toxicities occur, and this is especially true in the case of prostate cancer."
"The ArteraAI test is an AI that will look at an image of a patient's tumor, specifically a digitized image of the patient's histopathology of a biopsy or surgical specimen. It will look at all the patient's cells and the tumor morphology and the tumor microenvironment, everything else that you'll see on a histopathology slide in the form of a digital image. From that, it'll generate a report for the patient's clinician with two pieces of really important information on it. The first piece is how that patient will respond to therapy. The AI will predict the response to therapy. The second piece is prognostic information. So, the AI will prognosticate patient outcomes. Outcomes here mean will the patient's cancer metastasize in the next five or 10 years, will the patient die of cancer, will dangerous biochemical levels recur in time and so forth. And in doing so, we help to inform treatments."
#Artera #MedAI #AI #ProstateCancer #CancerDiagnostics #Tumors #HealthEquity
